DALLAS, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Puration, Inc. (USOTC: PURA) today confirmed signing its first distribution agreement for its EVERx CBD Sports Water in Latin American.  Management plans to publish more details later this week on Thursday, October 17^th regarding PURA’s strategy for the Latin American CBD market estimated to reach $2 billion by 2026. The Thursday update will include a PURA sales target for Latin America.  PURA has reported over $1 million in CBD beverage sales in the first six months of 2019 after reporting approximately $1 million in sales for all of 2018.  On top of its ongoing sales, PURA has signed a new European distribution agreement anticipated to generate $4 million annually with a first shipment scheduled later this month.  Earlier today, PURA announced an anticipated increase in sales from Canada resulting from Cannabis 2.0, the legalization of cannabis infused edibles and beverages in Canada going into effect later this week on October 17^th. 

In a recently published analyst report on PURA, the analyst highlighted Latin America as an untapped opportunity for CBD Beverages:

“An Untapped Opportunity. Most CBD analysts, companies, and investors are focused on the North American markets, and to some degree, Europe. However, a burgeoning untapped opportunity exists in the Caribbean markets. Countries such as Trinidad are set to legalize CBD and cannabis for the first time, creating an untapped, near-shore market opportunity.”

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350